HIV and hepatitis C co-infection: Acute HCV therapy

Current Opinion in HIV and AIDS

Volumn 6, Issue 6, 2011, Pages 459-464

  Boesecke, Christoph ^a   Vogel, Martin ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

acute hepatitis C virus; HIV; interferon; ribavirin; treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERLEUKIN 28B; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; DISEASE COURSE; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LIVER FIBROSIS; MALE HOMOSEXUAL; MIXED INFECTION; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEROCONVERSION; SEXUAL BEHAVIOR; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRUS LOAD;

ANTIVIRAL AGENTS; COINFECTION; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; INTERFERON-ALPHA; MALE; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 80054963278     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32834b87de     Document Type: Review

References (62)

1. Browne R, Asboe D, Gilleece Y, et al. Increased numbers of acute hepatitis C infections in HIV positive homosexual men: is sexual transmission feeding the increase? Sex Transm Infect 2004; 80:326-327. (Pubitemid 39070800)
2. Gambotti L, Batisse D, Colin-de-Verdiere N, et al. Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001-2004. Euro Surveill 2005; 10:115-117.
3. Giraudon I, Ruf M, Maguire H, et al. Increase in diagnosed newly acquired hepatitis C in HIV-positive men who have sex with men across London and Brighton, 2002-2006: is this an outbreak? Sex Transm Infect 2008; 84:111-115. (Pubitemid 351497921)
4. Rauch A, Rickenbach M, Weber R, et al. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clin Infect Dis 2005; 41:395-402. (Pubitemid 41022120)
5. Ruf M, Cohuet S, Maguire H, et al. SNAHC Steering Group. Setting up an enhanced surveillance of newly acquired hepatitis C infection in men who have sex with men: a pilot in London and South East region of England. Euro Surveill 2008; 13:2.
6. Urbanus AT, van de Laar TJ, Stolte IG, et al. Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. AIDS 2009; 23:F1-F7.
7. Vogel M, Deterding K, Wiegand J, et al. Initial presentation of acute hepatitis C virus (HCV) infection among HIV-negative and HIV-positive individuals: experience from 2 large German networks on the study of acute HCV infection. Clin Infect Dis 2009; 49:317-319; author reply 9.
8. Gallotta G, Gali L, De Bona A, et al. Acute hepatitis C virus in HIV co-infected men who have sex with men: Milan, 1996-2007. In 4th International HIV and Hepatitis Co-infection; Madrid, Spain; 2008; abstract 47.
9. Larsen C, Alric L, Auperin I, et al. Acute hepatitis C in HIV-infected men who have sex with men in France in 2006 and 2007. In: 58th Annual Meeting of the American Association for the Study of the Liver, Boston, USA; 2007; abstract 894.
10. Clausen LN, Weis N, Astvad K, et al. Interleukin-28B polymorphisms are associated with hepatitis C virus clearance and viral load in a HIV-1-infected cohort. J Viral Hepat 2011; 18:e66-e74.
11. Bottieau E, Apers L, Van Esbroeck M, et al. Hepatitis C virus infection in HIVinfected men who have sex with men: sustained rising incidence in Antwerp, Belgium, 2001-2009. Euro Surveill 2010; 15:19673.
12. van der Helm JJ, Prins M, Del Amo J, et al. The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. AIDS 2011; 25:1083-1091.
13. Fierer D, Fishman S, Uriel A, et al. Characterization of an outbreak of acute HCV infection in HIV-infected men in New York city. In 16th Conference on Retroviruses and Opportunistic Infections; Montreal, Canada; 2009; abstract 802.
14. Luetkemeyer A, Hare CB, Stansell J, et al. Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. J Acquir Immune Defic Syndr 2006; 41:31-36. (Pubitemid 41786016)
15. Matthews G, Hellard M, Haber P, et al. Characteristics and treatment outcomes among HIV-infected individuals in the Australian trial in acute hepatitis C. Clin Infect Dis 2009; 48:650-658.
16. Schmidt AJ, Rockstroh JK, Vogel M, et al. Trouble with bleeding: risk factors for acute hepatitis C among HIV-positive gay men from Germany: a casecontrol study. PLoS One 2011; 6:e17781.
17. van de Laar T, Pybus O, Bruisten S, et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology 2009; 136:1609-1617.
18. Vogel M, van de Laar T, Kupfer B, et al. Phylogenetic analysis of acute hepatitis C virus genotype 4 infections among human immunodeficiency virus-positive men who have sex with men in Germany. Liver Int 2010; 30:1169-1172.
19. Matthews GV, Pham ST, Hellard M, et al. Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian trial in acute hepatitis C. Clin Infect Dis 2011; 52:803-811.
20. Thomson EC, Nastouli E, Main J, et al. Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV. AIDS 2009; 23:89-93.
21. Scott C, Day S, Low E, et al. Unselected hepatitis C screening of men who have sex with men attending sexual health clinics. J Infect 2010; 60:351-353.
22. Cicconi P, Cozzi-Lepri A, Phillips A, et al. Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy? AIDS 2007; 21:599-606.
23. Stellbrink HJ, Schewe CK, Vogel M, et al. Increasing numbers of acute hepatitis C infections in HIV-infected MSM and high reinfection rates following SVR. J Int AIDS Soc 2010; 13 (Suppl 4):200.
24. Lambers F, Prins M, Thomas X, et al. High incidence rate of HCV reinfection after treatment of acute HCV infection in HIV-infected MSM in Amsterdam. In: 18th Conference on Retroviruses and Opportunistic Infections, Boston, USA; 2011; poster #958.
25. Grebely J, Petoumenos K, Hellard M, et al. ATAHC Study Group. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology 2010; 52:1216-1224.
26. Jones L, Uriel A, Kaplan D, et al. Natural history and treatment outcome of acute hepatitis C with and without HIV co-infection in a North American cohort. In: AASLD 2008 Meeting; San Francisco, USA; 2008; abstract 1838.
27. Thomson E, Fleming VM, Main J, et al. Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut 2011; 60:837-845.
28. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. J Am Med Assoc 2000; 284:450-456. (Pubitemid 30484478)
29. Soriano V, Mocroft A, Rockstroh J, et al. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infectedpatients with anti-HCV antibodies in Europe. J Infect Dis 2008; 198:1337-1344.
30. Gilleece YC, Browne RE, Asboe D, et al. Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr 2005; 40:41-46. (Pubitemid 41233203)
31. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461:798-801.
32. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138:1338-1345; e1331-1337.
33. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
34. Arends JE, Lambers FA, van der Meer JT, et al. Treatment of acute hepatitis C virus infection in HIV+ patients: Dutch recommendations for management. Neth J Med 2011; 69:43-49.
35. Fierer DS, Uriel AJ, Carriero DC, et al. Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. J Infect Dis 2008; 198:683-686.
36. Vogel M, Page E, Boesecke C, et al. Liver fibrosis progression after acute HCV infection (AHC) in HIV-positive individuals. AIDS (submitted).
37. Vogel M, Boesecke C, Rockstroh JK. Acute hepatitis C infection in HIVpositive patients. Curr Opin Infect Dis 2011; 24:1-6.
38. Vogel M, Page E, Matthews G, et al. Use of week 4 HCV RNA after acute HCV infection to predict chronic HCV infection. In 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, California, USA; 2010; abstract 640.
39. Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125:80-88. (Pubitemid 36799109)
40. Deterding K, Gruner NH, Wiegand J, et al. Early versus delayed treatment of acute hepatitis C: the German HEP-NET Acute HCV-III study: a randomized controlled trial. In: 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009); 2009; abstract 1047.
41. Dore GJ, Hellard M, Matthews GV, et al. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology 2010; 138:123.e1-2-135.e1-2.
42. The European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel. Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. AIDS 2010.
43. Boesecke C, Rockstroh JK. Treatment of acute hepatitis C infection in HIV-infected patients. Curr Opin HIV AIDS 2011; 6:278-284.
44. Vogel M, Nattermann J, Baumgarten A, et al. Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals. Antivir Ther 2006; 11:1097-1101. (Pubitemid 44955186)
45. Schnuriger A, Dominguez S, Guiguet M, et al. ANRS HC EP21 study group. Acute hepatitis C in HIV-infected patients: rare spontaneous clearance correlates with weak memory CD4 T-cell responses to hepatitis C virus. AIDS 2009; 23:2079-2089.
46. Dominguez S, Ghosn J, Valantin MA, et al. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS 2006; 20:1157-1161. (Pubitemid 43786104)
47. Kruk A. Efficacy of acute HCV treatment with peg-interferon alfa-2b and ribavirin in HIV-infected patients. In 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment; Rio de Janeiro; 2005; abstract TuPe1.C01.
48. Serpaggi J, Chaix ML, Batisse D, et al. Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy. AIDS 2006; 20:233-240.
49. Piroth L, Larsen C, Binquet C, et al. Steering Committee of the HEPAIG Study. Treatment of acute hepatitis C in human immunodeficiency virusinfected patients: the HEPAIG study. Hepatology 2010; 52:1915-1921; doi: 10.1002/hep.23959..
50. Nunez M, Miralles C, Berdun MA, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses 2007; 23:972-982. (Pubitemid 47492337)
51. Vogel M, Ahlenstiel G, Hintsche B, et al. The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive individuals. Eur J Med Res 2010; 15:102-111.
52. Arends J, Mudrikova T, Wensing A, et al. High percentage of nonresponse with peginterferon-alfa-2a monotherapy for the treatment of acute hepatitis C in HIV infected patients. In: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2009); San Francisco, USA; 2009;abstract H-222.
53. MatthewsG, Grebely J, Hellard M, et al. Differences in early virological decline in individuals treated within the Australian trial in acute HCV suggest a potential benefit for the use of ribavirin. In: 45th Annual Meeting of the European Association for the Study of the Liver (EASL). Vienna, Austria; 2010: Abstract O60.
54. Hare B, Marks K, Luetkemeyer A, et al. Kinetically guided PEG Alfa-2a and RBV therapy for HIV+ adults with acute HCV infection. In: 17th Conference on Retroviruses and Opportunistic Infection; San-Francisco, California, USA; 2010; abstract 639.
55. Hare B, Marks K, Luetkemeyer A, et al. Kinetically guided PEG Alfa-2a and RBV therapy for HIV+ adults with acute HCV infection. In: 18th Conference on Retroviruses and Opportunistic Infection; Boston, USA; 2010; abstract Q-134.
56. Nattermann J, Vogel M, Nischalke HD, et al. Genetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIV-positive patients with acute and chronic hepatitis C. J Infect Dis 2011; 203:595-601.
57. Neukam K, Nattermann J, Rallón N, et al. Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype. HIV Med 2011. doi: 10.1111/ j.1468-1293.2011.00912.x. [Epub ahead of print]
58. Boesecke C, Stellbrink HJ, Mauss S, et al. Does baseline HCV genotype have an impact upon treatment outcome of acute HCV infection in HIV co-infected individuals? In: 18th Conference on Retroviruses and Opportunistic Infections, Boston, USA; 2011, abstract #Q-138.
59. Vogel M, Dominguez S, Bhagani S, et al. Treatment of acute HCV infection in HIV-positive patients: experience from a multicentre European cohort. Antivir Ther 2010; 15:267-279.
60. Lambers F, Brinkman K, Schinkel J, et al. Treatment of acute hepatitis C virus infection in HIV-infected MSM: the effect of treatment duration. AIDS 2011. [Epub ahead of print]
61. Matthews GV, Dore GJ. Optimal duration of treatment for acute hepatitis C in human immunodeficiency virus-positive individuals? Hepatology 2011; 53:1055-1056 [author reply 1056-1057. doi: 10.1002/hep.24152].
62. Carlsson T, Quist A, Weiland O, et al. Rapid viral response and treatment outcome in genotype 2 and 3 chronic hepatitis C: comparison between two HCV RNA quantitation methods. J Med Virol 2008; 80:803-807. (Pubitemid 351500027)